Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants

Prakash, Satyendra

doi:10.1016/j.dsx.2022.102482

Cited by 15 publications

(9 citation statements)

References 57 publications

(93 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the top ten most cited publications, three papers in this cluster, which reported the results of safety and effectiveness of three vaccines, the ChAdOx1 nCoV-19 vaccine (AZD1222), the BNT162b2 mRNA vaccine, and the mRNA-1273 vaccine, yielded more than 4760 citations [ 17 , 18 , 20 ]. In a recent systematic review and meta-analysis, outcomes suggest that COVID-19 vaccines are effective in reducing the incidence of SARS-CoV-2 infection and have negligible adverse effects; this confirmed the effectiveness and safety of the COVID-19 vaccine after vaccination [ 51 , 52 ]. However, these vaccines achieved about 62–94% effectiveness against original SARS-CoV2 in clinical trials [ 20 ].…”

Section: Discussionmentioning

confidence: 87%

A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19)

et al. 2023

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), beginning in December 2019, has spread worldwide, leading to the death of millions. Owing to the absence of definitive treatment, vaccination against COVID-19 emerged as an effective strategy against the spread of the pandemic. Acceptance of the COVID-19 vaccine has advanced considerably, and vaccine-related research has significantly increased over the past three years. This study aimed to evaluate the content and external characteristics of COVID-19 vaccine-related literature for tracking research trends related to the global COVID-19 vaccine with the means of bibliometrics and visualization maps. A total of 18,285 records in 3499 journals were retrieved in the Web of Science Core Collection database and included in the final analysis. China was the first to focus on COVID-19 vaccine research, while European and American countries started late but developed rapidly. The USA and the UK are the top contributors to COVID-19 vaccine development, with the largest number of publications. The University of Washington and Harvard Medical School were the leading institutions, while Krammer, F. from Icahn School of Medicine at Mount Sinai was the author most active and influential to the topic. The New England Journal of Medicine had the highest number of citations and the highest TLS, and was the most cited and influential journal in the field of COVID-19 vaccine research. COVID-19 vaccine research topics and hotspots focused on populations’ attitudes towards vaccination, immunity-related information analysis of spike proteins, the effectiveness and side effects of the COVID-19 vaccine, and the public management of epidemic transmission. The findings of this study provide the global status, research hotspots and potential trends in the field of COVID-19 vaccine research, which will assist researchers in mastering the knowledge structure, and evaluating and guiding future developmental directions of COVID-19 vaccine

show abstract

Section: Discussionmentioning

confidence: 87%

A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19)

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Less frequently, cases of myocarditis or pericarditis have been reported. Among the more serious reactions that have occurred, death cases were not related to an anaphylactic or allergic reaction to the vaccine but to an aggravation of pre-existing chronic diseases (Castells et al 2009 ; Fazio et al 2022 ; Prakash 2022 ). The Pfizer/BioNTech and Moderna vaccines, both being based on the new technology of mRNA molecules, have been available on the market since the very beginning of the mass inoculation campaigns.…”

Section: Vaccinationsmentioning

confidence: 99%

Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic

Kapten

Orczyk

Smolewska

2023

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its mechanisms have been thoroughly studied by researchers all over the world with the hope of finding answers that may aid the discovery of new treatment options or effective means of prevention. Still, over 2 years into the pandemic that is an immense burden on health care and economic systems, there seem to be more questions than answers. The character and multitude of immune responses elicited in coronavirus disease 2019 (COVID-19) vary from uncontrollable activation of the inflammatory system, causing extensive tissue damage and consequently leading to severe or even fatal disease, to mild or asymptomatic infections in the majority of patients, resulting in the unpredictability of the current pandemic. The aim of the study was to systematize the available data regarding the immune response to SARS-CoV-2, to provide some clarification among the abundance of the knowledge available. The review contains concise and current information on the most significant immune reactions to COVID-19, including components of both innate and adaptive immunity, with an additional focus on utilizing humoral and cellular responses as effective diagnostic tools. Moreover, the authors discussed the present state of knowledge on SARS-CoV-2 vaccines and their efficacy in cases of immunodeficiency.

show abstract

“…The development of COVID-19 vaccine has been a top priority since the beginning of the pandemic, leading to an expedited t i m e l i n e f o r v a c c i n e d e v e l o p m e n t . S c i e n t i s t s a n d biopharmaceutical companies around the world have been working relentlessly to develop safe and effective vaccines to prevent COVID-19 (8). CoronaVac, an inactivated COVID-19 vaccine, was developed by Sinovac Life Sciences Co., Ltd. (hereafter referred to as Sinovac) beginning in early 2020.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity, safety and consistency of seven lots of an inactivated COVID-19 vaccine in healthy children and adolescents: a randomized, double-blind, controlled, phase IV clinical trial

Hu,

Liu,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundCoronaVac has been authorized worldwide for preventing coronavirus disease 2019. Information on the safety, immunogenicity and consistency of different lots and workshops of CoronaVac is presented here.MethodsIn this randomized, double-blind, phase IV clinical trial in healthy children and adolescents aged 3-17 years, we aimed to assess the lot-to-lot and workshop-to-workshop consistency, as well as immunogenicity and safety of seven lots of commercial-scale CoronaVac from three workshops. Eligible participants were enrolled into three age cohorts (3-5, 6-11 and 12-17 years). Within each cohort, participants were randomly assigned to seven groups to receive two doses of CoronaVac, with four weeks apart. Serum samples were collected before the first dose and 28 days after the second dose for neutralizing antibody testing. The primary objective was to evaluate the consistency of immune response among different lots within workshop 2 or 3, as well as among different workshops. The primary endpoint was geometric mean titer (GMT) of neutralizing antibody at 28 days after full-course vaccination.ResultsBetween July 27th and November 19th, 2021, a total of 2,520 eligible participants were enrolled. Results showed that 95% confidence intervals (CIs) of GMT ratios for all comparative groups among different lots or workshops were within the equivalence criteria of [0.67, 1.5]. The GMT and seroconversion rate for all participants were 126.42 (95%CI: 121.82, 131.19) and 99.86% (95%CI: 99.59%, 99.97%) at 28 days after two-dose vaccination. The incidences of adverse reactions were similar among seven lots, and most adverse reactions were mild in Grade 1, with no serious adverse event.ConclusionCoronaVac is well-tolerated and can elicit a good immune response among children and adolescents. Lot-to-lot consistency results indicate stable manufacturing of commercial-scale CoronaVac.

show abstract

Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants

Cited by 15 publications

References 57 publications

A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19)

A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19)

Immunity in SARS-CoV-2 Infection: Clarity or Mystery? A Broader Perspective in the Third Year of a Worldwide Pandemic

Immunogenicity, safety and consistency of seven lots of an inactivated COVID-19 vaccine in healthy children and adolescents: a randomized, double-blind, controlled, phase IV clinical trial

Contact Info

Product

Resources

About